Bufotenin (5-HO-DMT)

A tryptamine psychedelic (5-HO-DMT) found in some plant snuffs and toad secretions, used recreationally; not FDA-approved for medical use.

psilodex.org/m/bufotenin · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Bufotenin (5-HO-DMT)”, v2026.10.05. psilodex.org/m/bufotenin

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

Not FDA-approved

Availability

Illicit

01 Interaction with psilocybin

This psychedelic acts at the same receptors as psilocybin, so effects may add (not studied together). Separately, MAO inhibitors strengthen its effects.

Detail Bufotenin is a tryptamine psychedelic and a close chemical relative (an isomer) of psilocin. It acts at the same 5-HT2A and 5-HT2C receptors (McBride 2000). Its weak effects when given alone are attributed to poor entry into the brain. There are no data on combining it with psilocybin; in theory, combined effects are additive. Separately, in self-experiments, MAO-inhibiting beta-carbolines (harmine, harmaline) strengthened its effects (Ott 2001). Sources [1][2][3]

Human data with psilocybin: No psilocybin data; based on how it works and its label

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 2000;32(3):321–331. — Serotonergic: Abstract "recent experimental results showing activity similar to LSD and other known hallucinogens (psilocin and 5-MeO-DMT) at the purported hallucinogenic serotonin (5-HT) receptors, 5-HT2A and 5-HT2C."
Ott J. Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 2001;33(3):273–281. — Abstract: "Psychoptic (visionary) activity of bufotenine has been established" and MAOI beta-carboline potentiation "has been confirmed by 25 psychonautic bioassays."
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Psilocin is metabolized in part by MAO-A in vitro.

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →